Good news! Cancer is history!
This research was funded by the Lustgarten Foundation for Pancreatic Cancer Research ("the nation’s largest private funder of pancreatic cancer research")! "... At the time the Lustgarten Foundation was established [in 1999/2000], pancreatic cancer was an “orphan” disease with less than $16.2 million, or less than half of one percent of the total National Cancer Institute’s (NCI) budget supporting fewer than 15 researchers nationally. Because this was the only funding available at the time, young investigators opted not to dedicate their careers to the study of the disease. Knowing research follows dollars, in 2000, the Foundation awarded ten, $100,000 grants totaling $1 million to stimulate pancreatic cancer research. Over time, our support of pancreatic cancer research has stimulated the NCI to increase its pancreatic cancer research funding to more than $152 million in 2016 and inspired the creation of other pancreatic cancer organizations. Today, there are thousands of researchers from all disciplines working to solve this problem, many of whom are leaders in their fields."
What a pleasure garden (Lustgarten) to behold! 😃
What a pleasure garden (Lustgarten) to behold! 😃
"Pancreatic cancer, which affects about 60,000 Americans every year, is one of the deadliest forms of cancer. After diagnosis, fewer than 10 percent of patients survive for five years. While some chemotherapies are initially effective, pancreatic tumors often become resistant to them. The disease has also proven difficult to treat with newer approaches such as immunotherapy. ...
The new therapy, which is a combination of three drugs that help boost the body’s own immune defenses against tumors, is expected to enter clinical trials later this year. ...
However, when they combined CD40 agonist antibodies with both a PD-1 inhibitor and a TIGIT inhibitor, they found a dramatic effect. Pancreatic tumors shrank in about half of the animals given this treatment, and in 25 percent of the mice, the tumors disappeared completely. Furthermore, the tumors did not regrow after the treatment was stopped. ..."
However, when they combined CD40 agonist antibodies with both a PD-1 inhibitor and a TIGIT inhibitor, they found a dramatic effect. Pancreatic tumors shrank in about half of the animals given this treatment, and in 25 percent of the mice, the tumors disappeared completely. Furthermore, the tumors did not regrow after the treatment was stopped. ..."
The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer (open access)
No comments:
Post a Comment